Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715736 | 0.89 | HRH3 (0.43) | HRH3KMT2AMEN1PANK3HPGD | |
| SCHEMBL5715522 | 0.88 | HRH3 (0.44) | HRH3PANK3HPGDSMN1; SMN2CRBN | |
| SCHEMBL5715028 | 0.88 | TACR3 (0.43) | HRH3PANK3 | |
| SCHEMBL5904310 | 0.86 | AOC3 (0.40) | HRH3RAB9AHDAC1PANK3HPGD | |
| SCHEMBL5904386 | 0.85 | SMN1; SMN2 (0.55) | HRH3KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL5714761 | 0.85 | ALDH1A1 (0.46) | HPGDSMN1; SMN2 | |
| SCHEMBL5713912 | 0.85 | HRH3 (0.38) | HRH3KMT2AMEN1 | |
| SCHEMBL5715436 | 0.83 | HRH3 (0.41) | HRH3KMT2ANPC1RAB9AHDAC1 | |
| SCHEMBL5714963 | 0.82 | FAAH (0.36) | KMT2AMEN1 | |
| SCHEMBL5715146 | 0.81 | HTR3E (0.38) | KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | LIPE, PNLIP, LIPC | HRH3 1098/4885KMT2A 1641/4885NPC1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.